Citi analyst Samantha Semenkow initiated coverage of Biohaven (BHVN) with a Buy rating and $28 price target The company is therapies across neuroscience, immunology, and oncology, the analyst tells investors in a research note. Citi views the stock’s valuation as “de-risked” into the troriluzole FDA action date.
https://www.tipranks.com/news/the-fly/biohaven-initiated-with-a-buy-at-citi-thefly
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.